Your session is about to expire
← Back to Search
Radiation
Low-Dose Radiation for Marginal Zone Lymphoma
Phase 2
Recruiting
Led By Jillian Gunther, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests if lower doses of radiation therapy can help treat MZL, and if needed, escalate the dose.
Who is the study for?
This trial is for adults with stage I-II marginal zone lymphoma who can sign consent. It's open to those who've had prior treatments but still show signs of the disease, and not planning systemic therapy before follow-up. Participants must use birth control if they can have children, and cannot join if they're pregnant or have certain psychiatric conditions that affect compliance.
What is being tested?
The study tests ultra-low dose radiation therapy as a primary treatment for marginal zone lymphoma. Patients start with low doses which may be increased based on their response to the initial treatment, aiming to control the disease with minimal exposure.
What are the potential side effects?
While specific side effects are not listed here, radiation therapy generally can cause fatigue, skin irritation at the treated site, mild swelling or pain in nearby tissues, and sometimes nausea depending on the area being treated.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Ultra Low Dose 4 Gy RadiationExperimental Treatment1 Intervention
Participants will receive the ultra-low doses of radiation therapy over 1-2 days
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,074 Previous Clinical Trials
1,803,297 Total Patients Enrolled
260 Trials studying Lymphoma
32,535 Patients Enrolled for Lymphoma
Jillian Gunther, MDPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.I have had a condition where my lymphocytes grow abnormally.I am not scheduled for any drug treatments before my first check-up after radiation.I am currently being treated for active scleroderma.I have had previous treatments for my condition, regardless of type or amount.I agree to use effective birth control during the study.I have another cancer that won't affect this treatment.I have used antibiotics or creams for lymphoma treatment.I have received radiation at a site beyond safe levels.My tumor is larger than 7.5 cm.My condition is early-stage marginal zone lymphoma.My lymphoma diagnosis is not marginal zone lymphoma.I have not had any cancer in the last 5 years.I am a woman who can have children and my pregnancy test is negative.I have signs of cancer after treatment, confirmed by a biopsy or scans.
Research Study Groups:
This trial has the following groups:- Group 1: Ultra Low Dose 4 Gy Radiation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.